Crescent Biopharma (CBIO) Free Cash Flow (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Free Cash Flow of -$19.5 million for Q2 2026, down 17.74% year-over-year from -$23.7 million in Q2 2025, and down 114.4% quarter-over-quarter from -$9.1 million in Q1 2026.
Crescent Biopharma (CBIO) Free Cash Flow (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Free Cash Flow for 14 consecutive years, with -$19.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Free Cash Flow fell 17.74% year-over-year to -$19.5 million; the TTM figure through Jun 2026 stood at -$73.6 million (down 118.7% YoY), while the FY2025 annual figure was -$72.5 million, down 132.89% from the prior year.
- Free Cash Flow fell to -$19.5 million in Q2 2026 per CBIO's latest filing, from -$9.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$6.3 million in Q4 2024 and bottomed at -$26.9 million in Q4 2025.
- Historically, Free Cash Flow has averaged -$12.2 million across 5 years, with a median of -$10.5 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow surged 57.07% — and 2025, when it plunged 329.49%.
- Crescent Biopharma's Free Cash Flow stood at -$7.9 million in 2022, then gained by 3.74% to -$7.6 million in 2023, then increased by 17.68% to -$6.3 million in 2024, then slumped by 329.49% to -$26.9 million in 2025, then gained by 27.67% to -$19.5 million in 2026.
- Business Quant data shows CBIO's Free Cash Flow at -$19.5 million in Q2 2026, -$9.1 million in Q1 2026, and -$26.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | -19.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.48 Mn |
| Jun 30, 2026 | -19.48 Mn |
| Mar 31, 2026 | -9.05 Mn |
| Mar 31, 2026 | -9.05 Mn |
| Dec 31, 2025 | -26.66 Mn |
| Dec 31, 2025 | -26.66 Mn |
| Sep 30, 2025 | -17.53 Mn |
| Sep 30, 2025 | -17.53 Mn |
| Jun 30, 2025 | -16.50 Mn |
| Jun 30, 2025 | -16.50 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Dec 31, 2024 | -6.27 Mn |
| Jun 30, 2024 | -8.89 Mn |
| Jun 30, 2024 | -8.89 Mn |
| Mar 31, 2024 | -10.52 Mn |
| Mar 31, 2024 | -10.52 Mn |
| Dec 31, 2023 | -7.62 Mn |
| Dec 31, 2023 | -7.62 Mn |